List view / Grid view
UK biotech commits to scale up of 228Th extraction and a long-term supply agreement to facilitate production of thousands of doses of 212Pb for cancer therapies annually.
The investigational dual-targeting treatment provided strong and durable delivery to tumours, allowing for a high dose of targeted radiation, early results show.
The recommendations are issued amid increasing pressure on the complex supply chain for radiopharmaceuticals, medicines which are used to treat conditions such as cancer.
